Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Funding
Endure Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy
Details : The funding will support the development of a novel Engineered Native Bacteria (ENB) candidate for the treatment of Familial Adenomatous Polyposis (FAP).
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
August 12, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Funding